WARP Inhibitors
WARP Inhibitors encompass a group of chemical compounds that contribute to the stabilization of the extracellular matrix (ECM), where WARP is functionally active. Marimastat and Batimastat, as matrix metalloproteinase inhibitors, play a critical role in preserving the ECM by preventing the degradation of its components. This preservation is vital for the integrity of WARP's functional environment. Suramin, by inhibiting growth factor interactions with their receptors, and Cilengitide, by antagonizing integrins, both contribute to ECM stability, which is necessary for the functional stability of WARP. Bortezomib, a proteasome inhibitor, can also lead to the accumulation of ECM proteins, further supporting the ECM structure and WARP's associated functions.
Other compounds, such as Temozolomide and Thalidomide, contribute to maintaining ECM integrity by modifying the DNA of cells producing ECM-degrading enzymes and suppressing pro-inflammatory cytokines like TNF-α, respectively. Tranilast and Pirfenidone further support ECM stability by inhibiting mediators involved in ECM remodeling and reducing the synthesis of TGF-β, a key cytokine in these processes. Halofuginone's role in inhibiting collagen synthesis and TGF-β signaling also aids in preserving the ECM framework, thereby indirectly protecting WARP's function. Additionally, EDTA chelates metal ions necessary for metalloproteinase activity, thus indirectly preserving ECM integrity, and Tyrphostin B42's inhibition of JAK2/STAT3 signaling decreases ECM remodeling gene expression, which can indirectly stabilize WARP's functional activity within the ECM. Together, these inhibitors underscore a multi-faceted approach to indirectly sustain the ECM environment, thus preventing the functional inhibition of WARP.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
A broad-spectrum matrix metalloproteinase inhibitor that prevents the degradation of the extracellular matrix (ECM). As WARP is associated with the ECM, inhibiting matrix metalloproteinases can help preserve the ECM structure, thereby maintaining WARP's functional context and preventing its functional inhibition via ECM destabilization. | ||||||
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $179.00 $377.00 | 24 | |
Another matrix metalloproteinase inhibitor which, like Marimastat, helps to conserve the ECM integrity. This conservation is essential for WARP, which interacts with the ECM, to maintain its functional activity. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
A polysulfonated naphthylurea that inhibits the interaction of growth factors with their receptors. By blocking these interactions, Suramin indirectly diminishes the signaling pathways that could lead to ECM remodeling, thereby indirectly supporting WARP's role in the ECM. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
An integrin antagonist that inhibits the action of integrins involved in cell adhesion to the ECM. Since WARP is part of the ECM, blocking integrin function can stabilize the ECM structure and indirectly prevent the functional inhibition of WARP. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can lead to the accumulation of ECM proteins by preventing their degradation. An increase in ECM proteins can support the structural framework where WARP operates, thus indirectly avoiding its functional inhibition. | ||||||
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $91.00 $255.00 | 32 | |
An alkylating agent that, while primarily used as an antineoplastic agent, can modify the DNA of cells that produce ECM-degrading enzymes. This modification can lead to decreased expression of those enzymes, thus supporting ECM integrity and indirectly WARP's function. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Can suppress tumor necrosis factor-alpha (TNF-α), a cytokine involved in inflammation and ECM degradation. By suppressing TNF-α, Thalidomide indirectly helps to maintain ECM structure and thus WARP's functional stability. | ||||||
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | $31.00 $103.00 $283.00 $978.00 | 2 | |
Inhibits the release of cytokines and other mediators involved in ECM remodeling. By inhibiting these factors, Tranilast can help maintain the ECM structure and indirectly prevent the functional inhibition of WARP. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $102.00 $416.00 | 6 | |
An anti-fibrotic agent that reduces the synthesis of TGF-β, a key cytokine in ECM synthesis and remodeling. Reducing TGF-β levels can help to stabilize the ECM and thus indirectly prevent WARP inhibition. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1775.00 | ||
An inhibitor of collagen type I synthesis and an inhibitor of TGF-β signaling. By inhibiting these pathways, Halofuginone contributes to preserving ECM structure, indirectly supporting the functional integrity of WARP. | ||||||